Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
On March 8, AdaptVac announced that the clinical trial application (CTA) for a clinical phase I/II study for their ABNCoV2 COVID-19 vaccine has been approved by the Central Committee on Research Involving Human Subjects (CCMO), in the Netherlands. During the development process, the vaccine has been analyzed and validated using Attana's QCM biosensor.
AdaptVac initiates clinical phase I/II study for their new COVID-19 vaccine
The Central Committee on Research Involving Human Subjects (CCMM) in the Netherlands has approved the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine for clinical phase I/II study. The development was made possible by a collaboration between ExpreS[2]ion Biotechnologies, Bavarian Nordic, AdaptVac, University of Copenhagen, AGC, BioConnection and Radboud University Medical Center.
"If the results of the clinical test are just as promising as we expect them to be, we hope the vaccine will be ready by the end of 2021 or beginning of 2022" says Associate Professor Morten Agertoug Nielsen.
Attana's involvement
Attana has since March 2020 assisted in the development of the vaccine and contributed with two QCM biosensors to Prof. Salanti and his team at University of Copenhagen. Attana's biosensors have been used for analysis of the kinetic interactions between RBD-antigen and CLP-RBD to hACE2. Moreover, Attana's technology has been utilized in quality controls of the vaccine before the clinical trial application.
Attana's CEO, Teodor Aastrup comments:
"I am very happy for our partners and want to congratulate all of the involved parties on this achievement. We are eagerly looking forward to the release of the initial clinical trials results for Prof. Salanti's vaccine."